<DOC>
	<DOC>NCT02305316</DOC>
	<brief_summary>Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.</brief_summary>
	<brief_title>Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone</brief_title>
	<detailed_description>Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more. A total of twenty-eight (28) healthy volunteers received a single dose of 50 mg OPC, orally.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>A signed and dated informed consent form (ICF) before any studyspecific screening procedure was performed, Male or female subjects aged 18 to 45 years, inclusive, Body mass index (BMI) between 19 and 30 kg/m2, Healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination and 12lead electrocardiogram (ECG), Negative tests for hepatitis B surface antigen (HBsAg), antihepatitis C virus (HCV) antibodies and antihuman immunodeficiency virus (HIV) antibodies at screening, Clinical laboratory test results clinically acceptable at screening and on D1 of each treatment period, Negative screen for alcohol and drugs of abuse at screening and on D1 of each treatment period, Nonsmokers or exsmokers for at least 3 months, Volunteer able to participate, and willing to give written informed consent and comply with the study restrictions, If female: Was not of childbearing potential by reason of surgery or, if of childbearing potential, uses an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject) for the entire duration of the study, Negative serum pregnancy test at screening and a negative urine pregnancy test on D1 of each treatment period. Any clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or had a clinically relevant surgical history, Any clinically relevant abnormality in the coagulation tests, Any clinically relevant abnormality in the liver function tests, History of relevant atopy or drug hypersensitivity, History of alcoholism and/or drug abuse, Current consumption of more than 14 units of alcohol per week [1 unit of alcohol = 280 mL beer (34°) = 100 mL wine (1012°) = 30 mL spirits (40°)], Any significant infection or known inflammatory process on screening or admission to each treatment period, Any acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period, Use of medicines within 2 weeks of admission to first period that could affect the subject's safety or other study assessments, in the investigator's opinion, Previously received opicapone, Involvement in other clinical trials of any type within 90 days prior to screening, Participation in more than 2 clinical trials within the 12 months prior to screening, Blood donation or received any blood transfusion or any blood products within the 3 months prior to screening, Vegetarian, vegan or had medical dietary restrictions, Subject not able to communicate reliably with the investigator, Subjects who were unlikely to cooperate with the requirements of the study, Subjects who were unwilling or unable to give written informed consent, If female: Pregnant or breastfeeding, If of childbearing potential, a positive serum pregnancy test, Volunteer who did not use an accepted effective contraceptive method or used oral contraceptives,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>